Indian Pharma Market Sees 14.1 Percent Growth In July Sales: AIOCD-AWACS Report
New Delhi: The Indian Pharmaceutical Market (IPM) has witnessed a significant growth of 14.1% in value and 7.3% in volume in the month of July across all the therapy areas, as per the data from market research firm All India Organization of Chemists and Druggists (AIOCD-AWACS).
The Indian Pharmaceutical Market (IPM) recorded sales of Rs 15,921 crore in July, according to the market research firm of All India Organization of Chemists and Druggists (AIOCD-AWACS).
In accordance with the All India Organization of Chemists and Druggists' (AIOCD-AWACS) market research, all therapy areas experienced highly encouraging growth in the month of July. For the month of July 22, the majority of the therapy areas displayed strong double-digit value growth. The survey found that every therapeutic category—aside from anti-infectives—saw double-digit growth.
The AIOCD data also asserted that the fastest-growing subareas were respiratory, which increased by 22.3%; gynaecology, which increased by 24.3%; chemotherapy, which increased by 28.4%; urology, which increased by 22.5%; ophthalmic, which increased by 18.8%; pain, which increased by 16.9%; and derma, which increased by 16.7%.
Furthermore, the report also noted that the return of non-emergency procedures and the flu season associated with the monsoon may have contributed to the expansion of the aforementioned categories.
The report also observed that a number of manufacturers have entered the market to take advantage of the Sitagliptin potential as the dynamics in the oral anti-diabetic sector are shifting as a result of the Sitagliptin going off-patent opportunity.
According to the data, the top three selling brands in India in July were Augmentin, commonly used to treat infections of the urinary tract, respiratory tract, ear, sinuses, and skin, marketed by GSK; anti-diabetic medicine Glycomet Tablet marketed by USV; and Mixtard,a human premix Insulin, marketed by Abbott.
Based on sales results, GSK's Augmentin dominated the list of highest-selling products this month, followed by anti-diabetic medicine Glycomet Tablet marketed by USV, Abbott's Mixtard, Sanofi's Lantus, Mankind's Manforce, Himalaya's LIV.52, and others.
Sun Pharma plus Ranbaxy topped the top 20 Corporates list with a MAT corporate growth of 18.8 percent in the month of April 21, with bonus units at full value, according to the report.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.